罗莫佐单抗用于研究期间发生骨折的患者:FRAME和ARCH 3期试验的事后分析
FRAME和ARCH 3期试验事后分析显示,第12个月前发生非椎体或椎体骨折在初始接受罗莫佐单抗治疗的绝经后骨质疏松女性中少于安慰剂或阿仑膦酸钠组。罗莫佐单抗组再发骨折风险更低且无骨折相关并发症,结果支持骨折后继续罗莫佐单抗治疗。
要点
- 第12个月前非椎体和椎体骨折发生率罗莫佐单抗组数值上低于对照组。
- 发生非椎体骨折者中,罗莫佐单抗组再发非椎体和后续椎体骨折数值上更低。
- 发生椎体骨折者中,罗莫佐单抗组再发椎体和后续非椎体骨折数值上更低。
核心结论
- 数据提示支持骨折后继续罗莫佐单抗治疗的有效性和安全性。
研究设计与样本
- FRAME(NCT01575834)和ARCH(NCT01631214)3期试验的事后分析,绝经后骨质疏松女性随机1:1接受罗莫佐单抗210 mg每月一次或对照(FRAME为安慰剂;ARCH为阿仑膦酸钠70 mg每周一次)治疗12个月,随后抗骨吸收治疗(FRAME为地舒单抗;ARCH为阿仑膦酸钠)。
- 评估第12个月前发生研究期间非椎体骨折或新发/加重椎体骨折患者的骨折和治疗中出现的不良事件(TEAE)发生率(至36个月)、骨密度变化及罗莫佐单抗使用时机。
- 因所用样本量限制,无法进行有意义的组间统计学比较。
主要发现
- 第12个月前研究期间非椎体和椎体骨折发生率:FRAME中罗莫佐单抗组1.6%和0.5% vs 安慰剂组2.1%和1.6%;ARCH中罗莫佐单抗组3.4%和3.3% vs 阿仑膦酸钠组4.6%和4.9%,罗莫佐单抗组数值上更低。
- 第12个月前发生非椎体骨折者中,再发非椎体和后续椎体骨折发生率:FRAME中罗莫佐单抗组3.6%(2/56)和1.8%(1/56) vs 安慰剂组9.2%(7/76)和3.9%(3/76);ARCH中罗莫佐单抗组10.0%(7/70)和5.7%(4/70) vs 阿仑膦酸钠组12.6%(12/95)和8.4%(8/95),罗莫佐单抗组数值上更低。
- 第12个月前发生椎体骨折者中,再发椎体和后续非椎体骨折发生率:FRAME中罗莫佐单抗组0.0%(0/17)和0.0%(0/17) vs 安慰剂组11.9%(7/59)和8.5%(5/59);ARCH中罗莫佐单抗组9.0%(6/67)和7.5%(5/67) vs 阿仑膦酸钠组15.0%(15/100)和16.0%(16/100),罗莫佐单抗组数值上更低。
- 第12个月前发生骨折的患者中,罗莫佐单抗组未报告骨折相关并发症。
- 骨密度增益罗莫佐单抗组数值上大于对照组。
临床怎么用
- 作者认为数据支持骨折后继续罗莫佐单抗治疗的有效性和安全性。
局限性
- 因所用样本量限制,无法进行有意义的组间统计学比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Post hoc analysis of FRAME and ARCH revealed that on-study nonvertebral and vertebral fractures by Month 12 were less common in women initially treated with romosozumab versus placebo or alendronate. Recurrent fracture risk was also lower in romosozumab‑treated patients, and there were no fracture‑related complications. Results support continuing romosozumab treatment post‑fracture. PURPOSE: Post hoc analysis evaluating efficacy and safety of romosozumab, administered in the immediate post‑fracture period, in the FRAME and ARCH phase 3 trials. METHODS: In FRAME (NCT01575834) and ARCH (NCT01631214), postmenopausal women with osteoporosis were randomized 1:1 to romosozumab 210 mg monthly or comparator (FRAME, placebo; ARCH, alendronate 70 mg weekly) for 12 months, followed by antiresorptive therapy (FRAME, denosumab; ARCH, alendronate). In patients who experienced on-study nonvertebral or new/worsening vertebral fracture by Month 12, we report the following: fracture and treatment‑emergent adverse event (TEAE) incidence through 36 months, bone mineral density changes (BMD), and romosozumab timing. Due to the sample sizes employed, meaningful statistical comparisons between treatments were not possible. RESULTS: Incidence of on-study nonvertebral and vertebral fractures by Month 12 was numerically lower in romosozumab- versus comparator-treated patients (FRAME, 1.6% and 0.5% versus 2.1% and 1.6%; ARCH, 3.4% and 3.3% versus 4.6% and 4.9%, respectively). In those who experienced on-study nonvertebral fracture by Month 12, recurrent nonvertebral and subsequent vertebral fracture incidences were numerically lower in patients initially treated with romosozumab versus comparator (FRAME, 3.6% [2/56] and 1.8% [1/56] versus 9.2% [7/76] and 3.9% [3/76]; ARCH, 10.0% [7/70] and 5.7% [4/70] versus 12.6% [12/95] and 8.4% [8/95], respectively). Among those with on-study vertebral fracture by Month 12, recurrent vertebral and subsequent nonvertebral fracture incidences were numerically lower with romosozumab versus comparator (FRAME, 0.0% [0/17] and 0.0% [0/17] versus 11.9% [7/59] and 8.5% [5/59]; ARCH, 9.0% [6/67] and 7.5% [5/67] versus 15.0% [15/100] and 16.0% [16/100], respectively). In patients with fracture by Month 12, no fracture‑related complications were reported in romosozumab-treated patients. BMD gains were numerically greater with romosozumab than comparators. CONCLUSION: Data suggest support for the efficacy and safety of continuing romosozumab treatment following fracture. TRIAL REGISTRATIONS: NCT01575834; NCT01631214.
引用
- Lane J, Langdahl B, Stone M, et al. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials. Osteoporos Int. 2024. PMID: 38573517. doi:10.1007/s00198-024-07049-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。